Table 2.
Changes in Scr and eGFR of the patients with Stage 3b-4 CKD in the two groups
| Variables | Niaoduqing particles (n = 146) | Placebo (n = 146) | Z* | P |
|---|---|---|---|---|
| Scr (μmol/L) | ||||
| 0 week | 191.6 (162.0, 223.8) | 185.0 (166.0, 226.0) | −0.083 | 0.933 |
| 8 weeks | 192.0 (163.8, 234.7) | 192.1 (169.0, 224.4) | 0.267 | 0.790 |
| 16 weeks | 200.0 (164.0, 242.0) | 189.5 (165.50, 229.0) | −0.862 | 0.388 |
| 24 weeks | 198.6 (164.7, 239.6) | 203.1 (172.9, 252.7) | 1.414 | 0.157 |
| ∆Scr | 1.1 (−13.0, 24.1) | 11.7 (−2.6, 42.9) | 2.642 | 0.008 |
| ∆Z | 902.5 | 2136.0 | ||
| ∆P | 0.026 | <0.001 | ||
| eGFR (ml·min−1·1.73 m−2) | ||||
| 0 week | 31.0 (24.0, 37.1) | 30.6 (24.6, 36.4) | 0.049 | 0.961 |
| 8 weeks | 30.4 (23.5, 36.9) | 29.6 (24.3, 36.34 | 0.467 | 0.641 |
| 16 weeks | 30.0 (22.7, 36.5) | 30.1 (23.9, 37.2) | 0.702 | 0.483 |
| 24 weeks | 29.4 (23.5, 35.9) | 28.0 (21.0, 34.3) | −1.735 | 0.083 |
| ∆eGFR | −0.2 (−4.3, 2.7) | −2.2 (−5.7, 0.8) | −2.408 | 0.016 |
| ∆Z | −647.5 | −1943.0 | ||
| ∆P | 0.111 | <0.001 |
Values are given as median (Q1, Q3). *Z statistical value of Wilcoxon's rank-sum test. eGFR: Estimated glomerular filtration rate; Scr: Serum creatinine; CKD: Chronic kidney disease; ∆Scr: Change in Scr between pre- and post-treatment; ∆eGFR: Change in eGFR between pre- and post-treatment; ∆Z: Statistical value of Wilcoxon's rank-sum test, comparison of the changes in Scr or eGFR between pre- and post-treatment; ∆P: Comparison of the changes in Scr or eGFR between pre- and post-treatment.